Abstract
Introduction It is observed that many healthcare workers got COVID-19 infection despite of completing both doses of Covishield vaccine. This study aimed to find real incidence of vaccine breakthrough infection.
Material and methods All hospital employees, who were fully vaccinated were included in study. Details about their vaccine side effects, infection prior to vaccination, post vaccination infection, severity of infection, hospital and ICU admission were noted.
Results None encountered any significant side effects of vaccine. Of the 461 participants – 86 (18.65%) got infection average 38 days (range 14-70days) after vaccination. As per the NIH classification, out of 86, disease was mild in 69(80.2%), moderate in 10(11.62%), severe in 6(6.97%) and critical in 1(1.16%). Of these, 10(11.62%) required hospital admission. Of these 10, 2 were shifted to ICU. Of the 2, One recovered while one died. Thus mortality was 1/86(1.6%).
Conclusion Breakthrough infection rate in health care workers was 18.65%. Moderate, severe or critical disease occurred in 19.7% participants even after two doses of vaccine. Mortality due to disease cannot be completely obviated due to vaccine. The vaccine was safe without any significant adverse events.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
CTRI/2021/06/034019
Funding Statement
No funding or conflict of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Full name of the ethics committee: Muljibhai Patel Society for Research in Nephro-Urology Ethics committee
Institutional affiliation of the ethics committee: Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India
Decision of the ethics committee: Muljibhai Patel Society for Research in Nephro-Urology Ethics committee approve the trial to be conducted in its presented form.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NA
